Advertisement

Targeted Radionuclide Tumor Therapy

Biological Aspects

  • Torgny Stigbrand
  • Jörgen Carlsson
  • Gregory P. Adams

Table of contents

  1. Front Matter
    Pages i-xiii
  2. Jörgen Carlsson, Torgny Stigbrand, Gregory P. Adams
    Pages 1-11
  3. Torgny Stigbrand, David Eriksson, Katrine Riklund, Lennart Johansson
    Pages 13-23
  4. Torgny Stigbrand, David Eriksson, Katrine Riklund, Lennart Johansson
    Pages 59-76
  5. Marion de Jong, Suzanne M. Verwijnen, Monique de Visser, Dik J. Kwekkeboom, Roelf Valkema, Eric P. Krenning
    Pages 117-144
  6. Øyvind S. Bruland, Dahle Jostein, Dag Rune Olsen, Roy H. Larsen
    Pages 181-194
  7. Hans Lundqvist, Bo Stenerlöw, Lars Gedda
    Pages 195-214
  8. David Eriksson, Katrine Riklund, Lennart Johansson, Torgny Stigbrand
    Pages 215-248
  9. Bo Stenerlöw, Lina Ekerljung, Jörgen Carlsson, Johan Lennartsson
    Pages 249-266
  10. David Eriksson, Katrine Riklund, Lennart Johansson, Torgny Stigbrand
    Pages 267-284
  11. David Eriksson, Katrine Riklund, Lennart Johansson, Torgny Stigbrand
    Pages 285-293
  12. Kevin M. Prise
    Pages 311-319
  13. Brian Marples, Sarah A. Krueger, Spencer J. Collis, Michael C. Joiner
    Pages 329-347
  14. Andrew M. Scott, Sze-Ting Lee
    Pages 349-385
  15. Torgny Stigbrand, Jörgen Carlsson, Gregory P. Adams
    Pages 387-397
  16. Back Matter
    Pages 399-402

About this book

Introduction

The last three decades have provided opportunities to explore the potential of treating malignant diseases with antibodies or other targeting molecules labelled with nuclides. The expanding array of new targeting molecules (recombinant antibodies or peptides) may increase the therapeutic efficacy. The title of this book "Targeted Radionuclide Tumor Therapy – Biological aspects" was selected to reinforce the concept that a major focus was devoted to understanding the biological effects of targeting and radiation. Furthermore, our rapidly expanding knowledge of low dose-rate effects, different types of cell death, autosensitization and the increasingly likely existence of cancer stem cells suggests to us that even more efficient approaches in targeting might be possible in the future.

The development of targeted therapy is a true multidisciplinary enterprise involving physician scientists from the fields of nuclear medicine, radiation therapy, diagnostic radiology, surgery, gynaecology, pathology and medical oncology/haematology. It also involves many preclinical scientists working with experimental animal models, immunochemistry, recombinant antibody technologies, radiochemistry, radiation physics and basic cell biology.

It is the ambition of the editors to enable deeper insights in the process of improving targeted therapy. We believe that the time now has come when targeted therapy can soon be added to standard oncology treatment regimens.

Keywords

Cancer Treatment Cure vs Palliation Monoclonal Antibodies Radioimmunotherapy Targeted Tumor Therapy Tumor surgery

Editors and affiliations

  • Torgny Stigbrand
    • 1
  • Jörgen Carlsson
    • 2
  • Gregory P. Adams
    • 3
  1. 1.Department of ImmunologyUniversity of UmeaUmeaSweden
  2. 2.Rudbeck LaboratoryUppsala UniversityUppsalaSweden
  3. 3.Department of Medical OncologyFox Chase Cancer CenterPhiladelphiaUSA

Bibliographic information